In recent years, new insulin analogues (AI) have been developed to try to address these needs, and various insulin therapy regimens have been proposed.
It should be borne in mind that new insulin preparations are much more expensive, which may limit their use. Factors such as the efficacy of treatment, its safety and patient satisfaction should be taken into account when deciding on the choice of therapy, but the cost of treatment cannot be ignored either, given that it is usually reimbursable from the budget. In this regard, insulin therapy should be individually selected taking into account the needs of patients, the goals of treatment, its safety and cost. The global insulin market is getting bigger and is projected to reach 76 billion tons. USD by 2023.
Given the fact that the majority of diabetes cases occur in low- and middle-income countries, the price of insulin should be seriously considered as one of the most important characteristics, and the marketing of the most expensive products should be more responsible than ever.
A large body of data has now been accumulated allowing comparison of recombinant human insulin (RI) with AI, including meta-analyses of comparative efficacy and safety, as well as cost-effectiveness data and data relating to the possible carcinogenic effects of new products.
In the following materials in this section, the authors offer an analysis of these data on the feasibility of using AI in comparison with RIL for patients with type 1 diabetes (DM1) and patients with type 2 diabetes (DM2) and their effectiveness in both types of DM.
My Diabetes Solutions
M.V. Neborachko, O.G. Phakadze
Given the fact that the majority of diabetes cases occur in low- and middle-income countries, the price of insulin should be seriously considered as one of the most important characteristics, and the marketing of the most expensive products should be more responsible than ever.
A large body of data has now been accumulated allowing comparison of recombinant human insulin (RI) with AI, including meta-analyses of comparative efficacy and safety, as well as cost-effectiveness data and data relating to the possible carcinogenic effects of new products.
In the following materials in this section, the authors offer an analysis of these data on the feasibility of using AI in comparison with RIL for patients with type 1 diabetes (DM1) and patients with type 2 diabetes (DM2) and their effectiveness in both types of DM.
My Diabetes Solutions
M.V. Neborachko, O.G. Phakadze